October 14, 2010 — The US Food and Drug Administration (FDA) has granted humanitarian use device designation for a diaphragm pacing system (NeuRx; Synapse Biomedical, Inc) in patients with amyotrophic ...

Oberlin-based Synapse Biomedical recently secured U.S. Food and Drug Administration premarket approval for its diaphragm pacing system for use in patients with spinal cord injuries (SCI) who rely on ...

April 19, 2005 — Implantation of a minimally invasive diaphragm pacing system (DPS) with therapeutic electrostimulation may help maintain diaphragm function and slow or arrest the rate of respiratory ...

OBERLIN, Ohio, April 5, 2023 /PRNewswire/ -- Synapse Biomedical, Inc. announced today that the FDA has granted premarket approval (PMA) of the NeuRx ® Diaphragm Pacing System (NeuRx DPS ®) for use in ...

Please provide your email address to receive an email when new articles are posted on . Synapse Biomedical has received premarket approval from the FDA for its NeuRx Diaphragm Pacing System, which ...

CLEVELAND — Medical technology that was created in Cleveland has been given emergency approval by the FDA to help patients wean off ventilators. Oberlin-based Synapse Biomedical, working with ...

The U.S. Food and Drug Administration recently announced that it approved the NeuRx DPS RA/4 Respiratory Stimulation System, an implantable electronic device that stimulates the diaphragm and allows ...

Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...

ALS (also known as Lou Gehrig's disease) attacks the nerve cells that control muscles, ultimately resulting in paralysis of all voluntary muscles, including those used for breathing. Average life ...

Synapse Biomedical Inc. has won breakthrough device designation from the FDA for its Transaeris system, a diaphragm pacing system (DPS) for use in weaning patients off mechanical ventilation. The ...